Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

22.19
-1.4300-6.05%
Post-market: 22.220.0300+0.14%19:53 EDT
Volume:2.63M
Turnover:59.15M
Market Cap:2.25B
PE:-27.40
High:23.79
Open:23.46
Low:21.97
Close:23.62
52wk High:36.44
52wk Low:13.53
Shares:101.47M
Float Shares:89.94M
Volume Ratio:0.97
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8100
EPS(LYR):-0.8100
ROE:-8.11%
ROA:-18.55%
PB:1.82
PE(LYR):-27.40

Loading ...

Beam Therapeutics Projects Cash Runway Into 2029

Reuters
·
Jan 12

Beam Therapeutics Inc - Risto-Cel Bla Submission Expected by Year-End 2026

THOMSON REUTERS
·
Jan 12

Beam Therapeutics Inc - to Announce New Liver-Targeted Program in H1 2026

THOMSON REUTERS
·
Jan 12

Beam Therapeutics Inc - FDA Alignment on Accelerated Approval Pathway for Beam-302

THOMSON REUTERS
·
Jan 12

Beam Therapeutics Sets Strategic Priorities for Its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends Its Operating Runway Through Commercial Transition

THOMSON REUTERS
·
Jan 12

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Benzinga_recent_news
·
Jan 01

Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON risto-cel Data in Sickle Cell Disease

Simply Wall St.
·
Dec 19, 2025

Beam Therapeutics Nets $255 Million From Orbital Therapeutics Sale

Reuters
·
Dec 12, 2025

Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial

Reuters
·
Dec 06, 2025

Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS
·
Dec 06, 2025

Beam Therapeutics (BEAM) Is Up 6.8% After Analyst Optimism Around Sickle Cell Base-Editing Progress - What's Changed

Simply Wall St.
·
Dec 05, 2025

Does Beam Therapeutics' $1.1B Cash Position and Clinical Progress Reinforce the BEAM Investment Case?

Simply Wall St.
·
Nov 19, 2025

Cathie Wood Bets Big on This Peter Thiel-Backed Coinbase Rival as Bitcoin Crashes Below $91,000

Benzinga
·
Nov 18, 2025

Beam Therapeutics’ BEAM-101: Advancements in Sickle Cell Disease Therapy and Manufacturing Efficiency Drive Buy Rating

TIPRANKS
·
Nov 14, 2025

RBC Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
Nov 06, 2025

Beam Therapeutics (BEAM) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Nov 05, 2025

CRSP, BEAM, ROKU, SOFI: Cathie Wood Pours $17 Million into Biotech Stocks, Trims Tech Favorites

TIPRANKS
·
Nov 05, 2025

Cathie Wood’s ARK Investment buys 291K shares of Beam Therapeutics today

TIPRANKS
·
Nov 05, 2025

Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses

Reuters
·
Nov 04, 2025

Beam Therapeutics reports third quarter cash position of $1.1 billion

Reuters
·
Nov 04, 2025